Bone Biologics Corporation (BBLG), a developer of orthobiologic products for spine fusion, has priced a public offering of 1,250,000 shares of common stock, Series D warrants, and Series E short-term warrants, each exercisable for one common share at $4.00 per share.
The Series D warrants will expire in five years, and the Series E in 18 months. Gross proceeds from the offering are expected to total $5.0 million, with potential for an additional $10.0 million if all warrants are exercised in cash.
H.C. Wainwright & Co. is the exclusive placement agent for the offering, which is expected to close around June 30, 2025, pending customary conditions. Bone Biologics plans to use the funds for clinical trials, IP expansion, working capital, and general corporate purposes.
BBLG currently trades at $4.84, or 16.3462% higher on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.